2002 AUG 27 - (NewsRx.com & NewsRx.net) -- Baxter Healthcare Corporation announced that it is launching an oral formulation of Mesnex (mesna) Tablets as a prophylactic agent to reduce the incidence of ifosfamide-induced hemorrhagic cystitis.
Bristol-Myers Squibb Oncology will be copromoting Mesnex (mesna) Tablets during the initial launch period, including support from the company's leading oncology sales force. Bristol-Myers Squibb Oncology currently markets and distributes intravenous Mesnex (mesna) Injection and Ifex (ifosfamide for injection) for Baxter.
Currently, cancer patients undergoing treatment with the chemotherapy agent ifosfamide also receive …
No comments:
Post a Comment